Isomorphic Labs, a young company whose artificial intelligence technology for drug research has already landed partnerships with big pharmaceutical companies,

一家年轻的企业，其用于药物研究的人工智能技术已经与大型制药公司达成了合作关系，

unveiled $600 million

公布了6亿美元

in new financing this week as it looks to advance its own drug pipeline.

本周进行了新的融资，以推进其自身的药物研发进程。

London-based Isomorphic is an autonomous subsidiary of Alphabet. It came from DeepMind, a different Alphabet subsidiary that uses machine learning to solve problems. Isomorphic was formed in 2021 to build on the success of DeepMind’s AlphaFold, a technology that successfully predicted how a protein would fold based on its amino acid sequence.

总部位于伦敦的Isomorphic是Alphabet旗下的自主子公司。它源自DeepMind，这是Alphabet另一家使用机器学习解决问题的子公司。Isomorphic成立于2021年，旨在基于DeepMind的AlphaFold技术取得的成功进一步发展，该技术成功预测了蛋白质如何根据其氨基酸序列进行折叠。

The company is led by founder and CEO Demis Hassabis, who also co-founded and leads DeepMind..

公司由创始人兼首席执行官 Demis Hassabis 领导，他同时还共同创立并领导着 DeepMind。

Early last year, Isomorphic revealed two partners:

去年年初，Isomorphic透露了两位合作伙伴：

Eli Lilly

礼来公司

and

和

Novartis

诺华

. Both alliances, which span the discovery of small molecules for multiple undisclosed targets, came with upfront cash and the potential for milestone payments.

这两个联盟涵盖了为多个未公开靶点发现小分子，均附带预付款和潜在的里程碑付款。

presented by

呈现者

Sponsored Post

赞助帖子

How to Improve Employee Benefits While Reducing Insurance Costs

如何在降低保险成本的同时提升员工福利

Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.

平衡医疗福利和保险成本需要研究。从成为差异卡会员到提供健康资源，有许多方法可以以低成本改善医疗保健。

By The Difference Card

通过差异卡

Isomorphic says its AI drug design engine has foundational AI models capable of working across multiple therapeutic areas and drug modalities. The company is not yet disclosing the targets or therapeutic areas of its internal research. But as an example of its capabilities, Isomorphic points to AlphaFold 3, which was released by the company and DeepMind last year.

Isomorphic 表示，其人工智能药物设计引擎拥有能够跨多个治疗领域和药物模式工作的基础人工智能模型。该公司尚未披露其内部研究的目标或治疗领域。但作为其能力的一个例子，Isomorphic 提到了去年由该公司与 DeepMind 发布的 AlphaFold 3。

This technology can predict the structure and interactions of all of life’s molecules..

这项技术可以预测所有生命分子的结构和相互作用。

Isomorphic said the new financing, its first external round, was led by Thrive Capital and included participation from GV and follow-on capital from earlier investor Alphabet. In addition to supporting its AI drug design engine, the capital will also help Isomorphic advance internal programs to the clinic..

Isomorphic 表示，这轮融资是其首轮融资，由 Thrive Capital 领投，GV 参与投资，早期投资者 Alphabet 也继续跟投。这笔资金除了用于支持其人工智能药物设计引擎外，还将帮助 Isomorphic 推进内部项目进入临床阶段。

Isomorphic’s large financing comes amid investment headwinds. Capital raised by biotech companies in the first quarter of this year comes out to about $13 billion, analysts at William Blair said in a research note. That’s well below the $25.7 billion raised in the first quarter of 2024 and it’s also below the $18.8 billion quarterly average last year.

Isomorphic的大额融资是在投资逆风中进行的。威廉布莱尔公司的分析师在一份研究报告中表示，今年第一季度生物技术公司筹集的资金约为130亿美元。这远低于2024年第一季度筹集的257亿美元，也低于去年每季度平均188亿美元的水平。

Though 2024 started strong, the firm notes that biotech funding has declined sequentially for four consecutive quarters..

尽管 2024 年开局强劲，但该公司指出，生物技术资金已连续四个季度出现环比下降。

Here’s a recap of other recent financings as the first quarter came to a close:

随着第一季度的结束，以下是其他近期融资的简要回顾：

Sponsored Post

赞助帖子

Consultants: Help Define What’s Next In Healthcare Benefits

顾问：帮助定义医疗福利的未来发展方向

Just complete our survey and you’ll receive a $20 Amazon gift card!

只需完成我们的调查，您将获得一张20美元的亚马逊礼品卡！

By MedCity News

由 MedCity News 发布

—AIRNA

—爱尔兰航空

raised $155 million

筹集了1.55亿美元

to advance to Phase 1/2 testing with AIR-001, a potential treatment for alpha-1 antitrypsin deficiency.

推进AIR-001（一种潜在的α-1抗胰蛋白酶缺乏症治疗药物）进入1/2期测试。

Venrock Healthcare Capital Partners led the Series B round, which was co-led by Forbion Growth. Here’s more about AIRNA’s RNA-editing therapy for AATD, which puts it in competition with Korro Bio and Wave Life Sciences, both in early clinical development with RNA-editing therapies for the rare liver protein deficiency..

Venrock Healthcare Capital Partners 领投了 B 轮融资，Forbion Growth 联合领投。以下是关于 AIRNA 针对 AATD 的 RNA 编辑疗法的更多信息，这使其与 Korro Bio 和 Wave Life Sciences 形成竞争，这两家公司都处于针对这种罕见肝蛋白缺乏症的 RNA 编辑疗法的早期临床开发阶段。

—Character Biosciences

—字符生物科学

pulled in $93 million

收入9300万美元

to reach the clinic with two internally discovered complement inhibitors, each in development for different stages of the dry form of age-related macular degeneration.

为了达到诊所，使用两种内部发现的补体抑制剂，每种都在针对年龄相关性黄斑变性干性形式的不同阶段进行开发。

The Series B financing was co-led by aMoon and Luma Group, both new investors in the startup. Character, a spinout of Clover Health, closed an

B轮融资由aMoon和Luma Group共同领投，这两家都是该初创公司的新投资者。Clover Health的衍生公司Character完成了

$18 million Series A financing in 2022

2022年1800万美元A轮融资

.

。

—Epicrispr Biotechnologies

—Epicrispr生物技术公司

raised $68 million

筹集了6800万美元

as it prepares for Phase 1 testing of EPI-321, an epigenetic therapy that addresses the underlying cause of facioscapulohumeral muscular dystrophy (FSHD).

随着EPI-321的第1阶段测试准备工作的进行，这是一种针对面肩肱型肌营养不良症（FSHD）根本原因的表观遗传疗法。

The South San Francisco-based biotech’s therapies come from Gene Expression Modulation System, a technology that enables precise and durable control of gene expression. Epicrispr

总部位于南旧金山的生物技术公司的疗法来自基因表达调节系统，该技术能够实现对基因表达的精确且持久的控制。Epicrispr

presented preclinical data

提供了临床前数据

for the FSHD therapy last fall during the European Society of Cell and Gene Therapy annual meeting.

去年秋天，在欧洲细胞与基因治疗学会年会上，FSHD疗法的相关讨论。

—Tempero Bio

—生物温度

closed $70 million

关闭了7000万美元

in funding to support TMP-301 for substance use disorders.

用于支持TMP-301治疗物质使用障碍的资助。

The Oakland based company plans to advance the drug candidate two Phase 2 tests, one in alcohol use disorder and the other in cocaine use. 8VC led Tempero’s Series B financing.

总部位于奥克兰的公司计划将该候选药物推进两项二期试验，一项针对酒精使用障碍，另一项针对可卡因使用。8VC领投了Tempero的B轮融资。

—Hillstar Bio

希尔施塔生物公司

launched with $67 million

以6700万美元启动

to support the development of immunotherapies for autoimmune diseases.

支持自身免疫性疾病免疫疗法的开发。

The Boston-based startup says its therapies selectively deplete pathogenic cells while preserving healthy ones. The company’s lead program targets TRBV9-positive T cells; a clinical trial is planned for 2026 with an initial focus on axial spondyloarthritis and potentially other immune and inflammatory disorders..

这家总部位于波士顿的初创公司表示，其疗法能够选择性地清除致病细胞，同时保留健康细胞。该公司的主要项目针对TRBV9阳性的T细胞；计划在2026年进行临床试验，最初聚焦于轴向脊柱关节炎，并可能涉及其他免疫和炎症性疾病。

—Flagship Pioneering revealed its latest AI startup, Lila Sciences.

旗舰先锋公司公布了其最新的人工智能初创公司Lila Sciences。

While Lila’s technology allows it to process large amounts of data and make predictions, and the company says its technology also helps scientists design and conduct new experiments, generating hypotheses and testing them in real-world environments.

虽然 Lila 的技术能够处理大量数据并做出预测，但该公司表示，其技术还有助于科学家设计和开展新的实验，在现实世界环境中生成假设并对其进行测试。

Lila isn’t developing its own drugs. Rather, it’s looking to strike up partnerships with other companies aiming to leverage the technology for applications ranging from drug R&D, carbon capture, and sustainable agriculture. While Flagship startups typically launch with $50 million from the startup creator, Lila is .

莉拉并不是在开发自己的药物，而是在寻求与其他公司的合作，旨在利用这项技术应用于从药物研发、碳捕获到可持续农业等领域。尽管Flagship的初创公司通常会从这家初创公司创建者那里获得5000万美元的启动资金，但莉拉却没有。

backed by $200 million

由2亿美元支持

in committed seed financing from a syndicate that includes General Catalyst, March Capital, and a subsidiary of the Abu Dhabi Investment Authority, among others.

来自包括General Catalyst、March Capital和阿布扎比投资局子公司等在内的财团的承诺种子融资。

—Augustine Therapeutics

—奥古斯丁治疗学

closed €78 million

关闭了7800万欧元

(about $85 million) for drugs that block the enzyme HDAC6 to treat neuromuscular, neurodegenerative, and cardio-metabolic diseases.

（约 8500 万美元）用于购买阻断 HDAC6 酶的药物，以治疗神经肌肉、神经退行性和心代谢疾病。

The Leuven, Belgium-based company will apply the new capital to Phase 1/2 testing of lead program AGT-100216, an experimental treatment for rare neuromuscular disorder Charcot-Marie Tooth disease. Novo Holdings and Jeito Capital co-led Augustine’s Series A financing.

总部位于比利时鲁汶的公司将把新的资金用于主要项目 AGT-100216 的 1/2 期测试，这是一种针对罕见神经肌肉疾病腓骨肌萎缩症的实验性治疗。诺和控股和 Jeito Capital 联合领投了 Augustine 的 A 轮融资。

—Osivax

—Osivax

raised €10 million

筹集了1000万欧元

to continue development of OVX836, a broad-spectrum influenza vaccine candidate that has reached Phase 2b testing.

继续开发已进入二期b阶段测试的广谱流感疫苗候选药物OVX836。

The financing, which Lyon, France-based Osivax described as the first close of a Series B financing, added new investor Meiji Seika Pharma Co.

总部位于法国里昂的Osivax公司将这笔融资描述为B轮融资的首次交割，新投资者明治制果药业株式会社加入。

—Montara Therapeutics’ expanded its seed round

—Montara Therapeutics扩大了其种子轮融资

by $20 million

达2000万美元

as the company advances its lead epilepsy program to the preclinical research that could support an investigational new drug application (IND).

随着公司推进其领先的癫痫项目，进行可能支持研究性新药申请（IND）的临床前研究。

San Francisco-based Montara develops “BrainOnly” drugs, therapies that selectively target the central nervous system while blocking harmful peripheral effects. With the expanded financing, the round now totals $28 million.

总部位于旧金山的蒙塔拉公司开发“仅作用于大脑”的药物，这些疗法选择性地针对中枢神经系统，同时阻止有害的周围效应。随着融资规模的扩大，此轮融资总额现已达到 2800 万美元。

—Ampersand Biomedicines revealed

——Ampersand生物医学公司透露

$65 million in financing

6500万美元的融资

to bring programs in immuno-oncology and immuno-inflammation into IND-enabling studies.

将免疫肿瘤学和免疫炎症领域的项目推进到可支持新药临床试验（IND）的研究阶段。

The Flagship Pioneering-founded startup develops biologic drugs from a

由Flagship Pioneering创立的初创公司开发生物药物

platform technology that identifies “addresses,” markers found on disease-driving targets

识别“地址”的平台技术，这些地址是疾病驱动目标上的标记物

but not on healthy cells. Eli Lilly joined Flagship in Ampersand’s Series B round, which comes two years after the drug discovery biotech’s launch.

但不会影响健康细胞。Eli Lilly与Flagship一同参与了Ampersand的B轮融资，这轮融资发生在该药物发现生物技术公司成立两年后。

—Arbor Biotechnologies

— Arbor生物技术公司

raised $73.9 million

筹集了7390万美元

to finance Phase 1/2 testing of its gene therapy for primary hyperoxaluria type 1, a rare enzyme deficiency.

为原发性高草酸尿症1型的基因疗法的1/2期测试提供资金，这是一种罕见的酶缺乏症。

In vivo editing by the Arbor gene therapy, ABO-101, is intended to knock down expression of the HAO1 gene that drives the disease. Arch Venture Partners and TCGX led the Series C round for Cambridge-based Arbor, whose last financing was a

Arbor基因疗法ABO-101的体内编辑旨在抑制驱动疾病的HAO1基因的表达。Arch Venture Partners和TCGX领投了这家位于剑桥的Arbor公司的C轮融资，其上一轮融资是

$215 million Series B round in 2021

2021年2.15亿美元的B轮融资

.

。

—RegCell

—再生细胞

announced its relocation

宣布了其搬迁计划

from Japan to Emeryville, California, as it progresses toward the clinic with an experimental regulatory T cell (Treg) treatment for autoimmune disease.

从日本到加利福尼亚州埃默里维尔，随着它朝着临床进展，开展了一项实验性的调节性T细胞（Treg）治疗自身免疫疾病的试验。

The technology of RegCell generates epigenetically reprogrammed, antigen specific Tregs intended to restore immune tolerance. The company is financially backed by $8.5 million in seed financing and up to $37.3 million in non-dilutive funding from The Japan Agency for Medical Research and Development..

RegCell技术生成表观遗传重编程的、抗原特异性的Tregs，旨在恢复免疫耐受。该公司获得了850万美元的种子轮融资，以及来自日本医疗研究开发机构高达3730万美元的非稀释性资金支持。

—Cambridge, U.K.-based Maxion Therapeutics

总部位于英国剑桥的Maxion Therapeutics公司

revealed £58 million

揭示了5800万英镑

(about $72 million) in financing to reach human testing with MAX001,

（约7200万美元）的融资，用于MAX001的人体试验，

a potential treatment for a spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease. The company’s drugs combine knottins, a type of protein, with antibodies. These “KnotBodies” are intended to modulate ion channels and G protein-coupled receptors. General Catalyst led Maxion’s Series A financing..

一种潜在的治疗多种炎症性疾病的方法，如特应性皮炎和炎症性肠病。该公司的药物将结蛋白（一种蛋白质）与抗体结合。这些“KnotBodies”旨在调节离子通道和G蛋白偶联受体。General Catalyst 领投了Maxion的A轮融资。

—Latigo Biotherapeutics

—拉提戈生物治疗公司

closed $150 million

关闭了1.5亿美元

in financing for its non-opioid pain drug pipeline.

用于其非阿片类止痛药管道的融资。

Latigo is in Phase 2 testing with lead program LTG-001, a blocker of a sodium channel called NaV1.8. That’s the same target as

Latigo正在进行第二阶段测试，其主导项目LTG-001是一种名为NaV1.8的钠通道阻滞剂。这个靶点与

Vertex Pharmaceuticals’ recently approved non-opioid pain drug, Journavx

Vertex Pharmaceuticals最近获批的非阿片类止痛药Journavx

. Blue Owl Capital led Latigo’s Series B round.

蓝猫头鹰资本（Blue Owl Capital）领投了Latigo的B轮融资。

—Curevo Vaccine

—Curevo疫苗

closed $110 million

关闭了1.1亿美元

to continue clinical development of amezosvatein, an experimental shingles vaccine.

继续临床开发实验性带状疱疹疫苗amezosvatein。

In addition to extending the Phase 2 program to an additional 640 participants, the company aims to finalize dose selection for the planned Phase 3 study. Seattle-based Curevo also said Moncef Slaoui, the former GSK vaccine executive and chief scientific advisor to Operation Warp Speed, has been named chair of the company’s board of directors.

除了将第二阶段项目扩展至另外640名参与者外，该公司还旨在为计划中的第三阶段研究最终确定剂量选择。总部位于西雅图的Curevo公司还表示，曾任职GSK疫苗部门高管并担任过“曲速行动”首席科学顾问的蒙塞夫·斯拉维已被任命为公司董事会主席。

Medixci led Curevo’s Series B financing..

Medixci领投了Curevo的B轮融资。

—Insilico Medicine, a company that employs generative AI to drug discovery and development,

—Insilico Medicine，一家利用生成式人工智能进行药物发现和开发的公司，

raised $110 million

筹集了1.1亿美元

for its pipeline and technology.

对于其管道和技术。

Its most advanced drug candidate is

其最先进的候选药物是

rentosertib (formerly ISM001-055), a small molecule in mid-stage clinical development for idiopathic pulmonary fibrosis

雷托塞替尼（以前称为ISM001-055），一种处于中期临床开发的小分子，用于特发性肺纤维化。

. A private equity fund of Value Partners Group led Insilico’s Series E financing.

Value Partners Group旗下的私募股权基金领投了Insilico的E轮融资。

—Vivace Therapeutics

维瓦斯治疗公司

raised $35 million

筹集了3500万美元

to advance a potentially first-in-class drug that addresses the Hippo pathway.

推进一种潜在的首创药物，该药物针对Hippo通路。

Lead Vivace drug VT3989 blocks TEAD proteins in this pathway, which contribute to cancer when dysregulated. VT3989 is being readied for Phase 3 testing in mesothelioma. RA Capital Management led the San Mateo, California-based biotech’s Series D financing.

Vivace公司的主导药物VT3989可阻断该通路中的TEAD蛋白，这些蛋白在失调时会促进癌症的发展。VT3989正准备进行间皮瘤的第三阶段测试。RA Capital Management领投了这家位于加利福尼亚州圣马特奥的生物技术公司的D轮融资。

—Callio Therapeutics

呼叫治疗公司

emerged with $187 million

带着1.87亿美元出现

for its new twist on antibody drug conjugates (ADC) for cancer.

由于其在癌症的抗体药物偶联物（ADC）方面的新变化。

Currently available ADCs carry a single drug payload. Callio, which splits its operations between Seattle and Singapore, is developing multi-payload ADCs. Frazier Life Sciences led Callio’s Series A financing, which it will use to achieve clinical proof of concept for a dual payload ADC targeting the cancer protein HER2.

目前可用的ADC仅携带单一药物载荷。Callio公司在西雅图和新加坡两地开展业务，正在开发多载荷ADC。Frazier生命科学领投了Callio公司的A轮融资，这笔资金将用于实现针对癌症蛋白HER2的双载荷ADC的临床概念验证。

The target of a second Callio program is undisclosed..

第二次卡利俄普计划的目标尚未披露。

—Garuda Therapeutics

—迦楼罗治疗公司

raised $50 million

筹集了5000万美元

to support its R&D of off-the-shelf hematopoietic stem cell therapies for potential applications in a range of blood disorders.

以支持其现成的造血干细胞疗法的研发，用于一系列血液疾病的潜在应用。

Investors in the Series A-1 round include OribiMed, Northpond Ventures, Cormorant Asset Management, and Japanese pharma company Kyowa Kirin.

A-1轮融资的投资者包括OribiMed、Northpond Ventures、Cormorant Asset Management以及日本制药公司协和麒麟。

—Cancer biotech Eikon Therapeutics

—癌症生物技术公司Eikon Therapeutics

closed $350 million

关闭了3.5亿美元

in financing to support a pipeline that includes lead program EIK1001, which is in Phase 3 testing in advanced melanoma.

在融资方面，以支持包括主导项目EIK1001在内的研发管线，EIK1001目前正在晚期黑色素瘤中进行第三阶段测试。

This drug is a small molecule that activates TLR7/8 receptors to spark an immune response against cancer.

这种药物是一种小分子，能够激活TLR7/8受体，从而激发针对癌症的免疫反应。

—Bambusa Therapeutics, startup developing bispecific antibodies applications in immunology and inflammation, said its Series A financing

—Bambusa Therapeutics，一家开发双特异性抗体在免疫学和炎症领域应用的初创公司，宣布了其A轮融资。

raised about $90 million

筹集了约 9000 万美元

.

。

Lead program BBT001 is being readied for Phase 1 testing in dermatological conditions. New investor RA Capital Management led the Boston-based biotech’s financing.

主导项目BBT001正准备进行针对皮肤病的1期临床测试。新投资者RA Capital Management领投了这家位于波士顿的生物技术公司的融资。

—Abcuro

—Abcuro

raised $200 million

筹集了2亿美元

to support ulviprubart, a drug in Phase 2/3 testing for inclusion body myositis, an autoimmune disease in which T cells chronically attack muscle tissue.

支持ulviprubart，这是一种处于2/3期测试的药物，用于治疗包涵体肌炎，一种T细胞长期攻击肌肉组织的自身免疫疾病。

The drug is an antibody that blocks a target called KLRG1. New Enterprise Associates led the Newton, Massachusetts-based biotech’s Series C financing.

该药物是一种阻断名为KLRG1的靶点的抗体。新企业联合公司（New Enterprise Associates）领投了这家位于马萨诸塞州牛顿的生物技术公司的C轮融资。

—Newleos Therapeutics unveiled clinical-stage neuropsychiatric drug candidates licensed from Roche and backed by

纽莱奥斯制药公司公布了从罗氏获得许可并得到支持的临床阶段神经精神药物候选药物

$93.5 million

9350万美元

in funding.

资金。

Lead Newleos program NTX-1955 target the GABA A receptor subunit gamma 1 as a potential treatment for anxiety. Newleos plans to advance this small molecule to proof-of-concept clinical testing in generalized anxiety disorder. Goldman Sachs Alternatives led Newleos’s Series A financing.

Newleos公司主导的NTX-1955项目针对GABA A受体γ1亚基，作为一种潜在的焦虑症治疗方法。Newleos计划将这一小分子推进到广泛性焦虑障碍的概念验证临床试验。高盛另类投资领投了Newleos的A轮融资。

Photo:

照片：

Devrimb

革命

, Getty Images

，Getty Images